Expression and bioactivity of recombinant 3DHSA-Nartograstim fusion protein in<i> Pichia pastoris</i>

ZHAO Shuqiang; ZHANG Yu; TIAN Hong; LIU Chao; GAO Xiangdong

doi:10.11665/j.issn.1000-5048.20130618

Journal of China Pharmaceutical University > 2013 > 44(6): 577-582. > DOI: 10.11665/j.issn.1000-5048.20130618

ZHAO Shuqiang, ZHANG Yu, TIAN Hong, LIU Chao, GAO Xiangdong. Expression and bioactivity of recombinant 3DHSA-Nartograstim fusion protein in Pichia pastoris[J]. Journal of China Pharmaceutical University, 2013, 44(6): 577-582. DOI: 10.11665/j.issn.1000-5048.20130618

Citation:

PDF (1452 KB)

Expression and bioactivity of recombinant 3DHSA-Nartograstim fusion protein in Pichia pastoris

More Information

Graphical Abstract

Abstract

Abstract

The gene for coding the fusion protein 3DHSA-Nartograstim was cloned into pPICzαA vector along with the open reading frame of the α-factor signal under the control of the AOX promoter. The recombinant secret expression plasmid was transformed into Pichia pastoris host strain GS115 by electroporation. The analysis of SDS-PAGE demonstrated that the relative molecular masses of 3DHSA-Nartograstim were about 42 kD, and the results of Western blotting proved that 3DHSA-Nartograstim was recognized specially by HSA and G-CSF antibodies. The established expression condition of 3DHSA-Nartograstim was BMMY pH 6. 0, 1. 5% methanol for 84 h, and gray scale scanning showed that the purity of 3DHSA-Nartograstim was 79%. Through the combination of affinity chromatography and hydrophobic chromatography, the purity of 3DHSA-Nartograstim was up to 90% and the final yield was 86 mg/L. The bioactivity of 3DHSA-Nartograstim was measured by NFS-60 proliferation assay. Results demonstrated that 3DHSA-Nartograstim could stimulate NFS-60 proliferation in a dose-dependent manner. The study would be helpful for further research of 3DHSA-Nartograstim.
- human serum albumin,
- granulocyte colony-stimulating factor,
- 3DHSA,
- Pichia pastoris

FullText(HTML)

References (23)

References

[1]	Clark SC,Kamen R.The human hematopoietic colony-stimulating factors[J].Science,1987,236(4 806):1 229-1 237.
[2]	Wittman B,Horan J,Lyman GH.Prophylactic colony-stimulating factors in children receiving myelosuppressive chemotherapy:a meta-analysis of randomized controlled trials[J].Cancer Treat Rev,2006,32(4):289-303.
[3]	Fujii I,Nagahara Y,Yamasaki M,et al.Structure of KW-2228,a tailored human granulocyte colony-stimulating factor with enhanced biological activity and stability[J].FEBS Lett,1997,410(2/3):131-135.
[4]	Schmidt SR.Fusion-proteins as biopharmaceuticals - applications and challenges[J].Curr Opin Drug Discov Devel,2009,12(2):284-295.
[5]	Theodore Peters Jr.All about Albumin:Biochemistry,Genetics and Meidical Applications[M].Oxford:Elsevier′s science and technology Rights Department,1995:415.
[6]	Zunszain PA,Ghuman J,Komatsu T,et al.Crystal structural analysis of human serum albumin complexed with hemin and fatty acid[J].BMC Struct Biol,2003,3:6.
[7]	Yeh P, Landais D, Lemaître M, et al. Design of yeast-secreted albumin derivatives for human therapy:biological and antiviral properties of a serum albumin-CD4 genetic conjugate[J].Proc Natl Acad Sci U S A,1992,89(5):1 904-1 908.
[8]	Halpern W, Riccobene TA, Agostini H, et al. Albugranin^TM,a recombinant human granulocyte colony stimulating factor(G-CSF)genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys[J].Pharm Res,2002,19(11):1 720-1 729.
[9]	Sung C, Nardelli B, LaFleur DW, et al. An IFN-beta-albumin fusion protein that displays improved pharmacokinetic and pharmacodynamic properties in nonhuman primates[J].J Interferon Cytokine Res,2003,23(1):25-36.
[10]	Duttaroy A,Kanakaraj P,Osborn BL,et al.Development of a long-acting insulin analog using albumin fusion technology[J].Diabetes,2005,54(1):251-258.
[11]	Müller D,Karle A,Meissburger B,et al.Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin[J].J Biol Chem,2007,282(17):12 650-12 660.
[12]	Yao XQ,Zhao HL,Xue C,et al.Degradation of HSA-AX15(R13K)when expressed in Pichia pastoris can be reduced via the disruption of YPS1 gene in this yeast[J].J Biotechnol,2009,139(2):131-136.
[13]	Cordes AA,Platt CW,Carpenter JF,et al.Selective domain stabilization as a strategy to reduce fusion protein aggregation[J].J Pharm Sci,2012,101(4):1 400-1 409.
[14]	Cordes AA,Carpenter JF,Randolph TW.Selective domain stabilization as a strategy to reduce human serum albumin-human granulocyte colony stimulating factor aggregation rate[J].J Pharm Sci,2012,101(6):2 009-2 016.
[15]	Andersen JT,Dee Qian J,Sandlie I.The conserved histidine 166 residue of the human neonatal Fc receptor heavy chain is critical for the pH-dependent binding to albumin[J].Eur J Immunol,2006,36(11):3 044-3 051.
[16]	Chaudhury C,Brooks CL,Carter DC,et al.Albumin binding to FcRn:distinct from the FcRn-IgG interaction[J].Biochemistry,2006,45(15):4 983-4 990.
[17]	Kenanova VE,Olafsen T,Salazar FB,et al.Tuning the serum persistence of human serum albumin domain III:diabody fusion proteins[J].Protein Eng Des Sel,2010,23(10):789-798.
[18]	Daly R,Hearn MT.Expression of heterologous proteins in Pichia pastoris:a useful experimental tool in protein engineering and production[J].J Mol Recognit,2005,18(2):119-138.
[19]	Dockal M,Carter DC,Rüker F.The three recombinant domains of human serum albumin structural characterization and ligand binding properties[J].J Biol Chem,1999,274(41):29 303-29 310.
[20]	Kobayashi K,Kuwae S,Ohya T,et al.High-level expression of recombinant human serum albumin from the methylotrophic yeast Pichia pastoris with minimal protease production and activation[J].J Biosci Bioeng,2000,89(1):55-61.
[21]	Sheffield WP,McCurdy TR,Bhakta V.Fusion to albumin as a means to slow the clearance of small therapeutic proteins using the Pichia pastoris expression system:a case study[J].Methods Mol Biol,2005(308):145-154.
[22]	Guo ZF,Duan ZY,Zhang LF,et al.Determination of thiopurine methyltransferase activity in human red blood cells by HPLC[J].J China Pharm Univ(中国药科大学学报),2008,39(1):82-86.
[23]	Chun E,Thompson AA,Liu W,et al.Fusion partner toolchest for the stabilization and crystallization of G protein-coupled receptors[J].Structure,2012,20(6):967-976.

[1]	CAI Yanfei, WAN Aini, CHEN Yun, JIN Jian. Anti-liver fibrosis activities of the extracellular domain of transforming growth factor beta type II receptor fusion protein in vivo[J]. Journal of China Pharmaceutical University, 2019, 50(2): 246-252. DOI: 10.11665/j.issn.1000-5048.20190217
[2]	LIANG Xiaoqing, YAN Pengfei, LIU Yu. Expression and purification of human placental growth factor 2 using the Pichia pastoris expression system[J]. Journal of China Pharmaceutical University, 2018, 49(3): 376-380. DOI: 10.11665/j.issn.1000-5048.20180318
[3]	Determination of thiopurine methyltransferase activity in human red blood cells by HPLC[J]. Journal of China Pharmaceutical University, 2008, 39(1): 82-86.
[7]	Yeast for New Drug Research[J]. Journal of China Pharmaceutical University, 2004, (6): 109-113.
[8]	Pichia Expression of Recombined Human VEGF165 and Activity Determination[J]. Journal of China Pharmaceutical University, 2004, (1): 84-87.
[9]	Pichia Expression of Human VEGF165[J]. Journal of China Pharmaceutical University, 2003, (6): 96-100.
[10]	Expression of Human Transforming Growth Factor β3 in E.coli BL21[J]. Journal of China Pharmaceutical University, 2003, (3): 70-73.

Cited By

Get Citation

PDF

XML

Article views (1504) PDF downloads (1964)

Turn off MathJax

Article Contents

Abstract

References

Expression and bioactivity of recombinant 3DHSA-Nartograstim fusion protein in Pichia pastoris

Abstract

References

Related Articles

Catalog

Expression and bioactivity of recombinant 3DHSA-Nartograstim fusion protein in Pichia pastoris

Abstract

References

Related Articles

Catalog

Export File

Citation

Format

Content